Xilio Therapeutics (XLO) revenue and earnings history
Xilio Therapeutics reported revenue of $43.8M for fiscal 2025 (year ended Dec 31, 2025), +589.9% on the year before, and net income of −$35M.
Over 1 years, from fiscal 2024 to fiscal 2025, revenue grew at a compound rate of +589.9% a year.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $43.8M+589.9% | −$42M | −$35M | −$4.99M | $518K | −$5.51M | $6.94M | — | — | $138M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Xilio Therapeutics (XLO) on OQRO.
Common questions
What was Xilio Therapeutics's revenue in fiscal 2025?
$43.8M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 23, 2026. That is +589.9% on fiscal 2024 ($6.34M).
How fast has Xilio Therapeutics's revenue grown?
From $6.34M in fiscal 2024 to $43.8M in fiscal 2025: a compound annual growth rate of +589.9% over 1 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Xilio Therapeutics been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Xilio Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
